Skip to main content
SpringerLink
Log in

Taxol: A new agent active in melanoma and ovarian cancer

  • Chapter
New Drugs, Concepts and Results in Cancer Chemotherapy

Part of the book series: Cancer Treatment and Research ((CTAR,volume 58))

Abstract

Taxol was isolated in 1971 from the stem bark of the plant Taxus brevifolia, (western yew), a small evergreen native to the Pacific Northwest, and its structure was characterized by Wani et al. [l]. This drug is a complex ester,consisting of a taxane derivative with an oxetan ring, an unusual chemical structure (as shown in figure 1) whose biological activity had not been previously studied.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Am Chem Soc 93:2325–2327, 1971.

    Article  CAS  Google Scholar 

  2. Schiff PB and Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565, 1980.

    Article  PubMed  CAS  Google Scholar 

  3. Crossin KL and Carney DH. Micro tubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 27:341–350, 1981.

    Article  PubMed  CAS  Google Scholar 

  4. DeBrabander M, Gruens G, Nuydens R, et al. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 78:5608–5612, 1981.

    Article  CAS  Google Scholar 

  5. DeBrabander M. A model for the microtubule organizing activity of the centrosomes and kinetochores in mammalion cells. Cell Biol Int Rep 6:901–915, 1982.

    Article  CAS  Google Scholar 

  6. Albertini DF and Clark JI. Visualization of assembled and disassembled microtubule protein by double label fluorescence microscopy. Cell Biol Int Rep 5:387–397, 1981.

    Article  PubMed  CAS  Google Scholar 

  7. Brenner SL and Brinkley BB. Tubulin assembly sites and the organization of microtubule arrays in mammalion cells. Cold Spring Harbor Symp Quant Biol. 46:241–254, 1982.

    PubMed  Google Scholar 

  8. Tokunaka S, Friedman TM, Toyama Y, et al. Taxol induces microtubule-rough endoplasmic reticulum complexes and microtubule-bundles in cultured chondroblasts. Differentiation 24:39–47, 1983.

    Article  PubMed  CAS  Google Scholar 

  9. Manfredi JJ, Parness J, and Horwitz SB, Taxol binds to cellular microtubules. J Cell Biol 94:688–696, 1982.

    Article  PubMed  CAS  Google Scholar 

  10. Schiff PB, Fant J, and Horwitz SB. Promotion of nicrotubule assembly in vitro by taxol. Nature (London) 277:665–667, 1979.

    Article  CAS  Google Scholar 

  11. Schiff PB and Horwitz SB: Tubulin: A target for chemotherapeutic agents. In: Molecular Actions and Targets for Cancer Chemotherapeutic Agents, Vol. 2, AC Sartorelli, JS Lazo, JR Bertino (eds). Bristol-Myers Cancer Symposium. Academic Press, New York, 1981, pp. 483–507.

    Google Scholar 

  12. Schiff PB and Horwitz SB: Taxol assembles tubulin in the absence of exogenous 5’-triphosphate or microtubule-associated proteins. Biochemistry 20:3247–3252, 1981.

    Article  PubMed  CAS  Google Scholar 

  13. Kumar N. Taxol-induced polymerization of purified tubulin. J Biol Chem 256:10435–10441, 1981.

    PubMed  CAS  Google Scholar 

  14. Parness J and Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479–487, 1981.

    Article  PubMed  CAS  Google Scholar 

  15. National Cancer Institute Clinical Brochure. Taxol (NSC 125973), 1990.

    Google Scholar 

  16. Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47:2486–2493, 1987.

    PubMed  CAS  Google Scholar 

  17. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5:1232–1239, 1987.

    PubMed  CAS  Google Scholar 

  18. Longnecker SW, Donehower RC, Cates AE, et al. High performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53–59, 1987.

    PubMed  CAS  Google Scholar 

  19. Legha SS, Tenney DM, and Krakoff IR. Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 4:762–766, 1986.

    PubMed  CAS  Google Scholar 

  20. Donehower RC, Rowinsky EK, Grochow LB, et al. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 71:1171–1177, 1987.

    PubMed  CAS  Google Scholar 

  21. Greenberger PA, Patterson R, Simon R, et al. Pretreatment of high risk patients requiring radiographic contrast media studies. J Allergy Clin Immunol 67:185–187, 1981.

    Article  PubMed  CAS  Google Scholar 

  22. Grem JL, Kendro DT, Simon KJ, et al. Phase I study of taxol administered as a short IV infusion daily for 5 days. Cancer Treat Rep 71:1179–1184, 1987.

    PubMed  CAS  Google Scholar 

  23. Kris MG, O’Connell JP, Gralla RJ. et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70:605–607, 1986.

    PubMed  CAS  Google Scholar 

  24. Ohnuma T, Zimet AS, Coffey VA, et al. Phase I study of taxol in a 24-hr. infusion schedule. Proc Ann Meet Am Assoc Cancer Res 26:167, 1985.

    Google Scholar 

  25. Koeller J, Brown T, Havlin K, et al. A phase I/pharmacokinetic study of taxol given by a prolonged infusion without premedication. Proc Ann Meet Am Soc Clin Oncol 8:82, 1989.

    Google Scholar 

  26. Rowinsky EK, Donehower RC, Jones RJ, et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093–4100, 1988.

    PubMed  CAS  Google Scholar 

  27. Einzig Al, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 9:59–64, 1991.

    Article  PubMed  CAS  Google Scholar 

  28. Legha SS, Ring S, Papadopoulus N, et al. Taxol: a phase II study in patients with malignant melanoma. Cancer 65:2478–2481, 1990.

    Article  PubMed  CAS  Google Scholar 

  29. Einzig Al, Gorowski E, Sasloff J, et al. Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9:133–136, 1991.

    Article  PubMed  CAS  Google Scholar 

  30. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273–279, 1989.

    PubMed  CAS  Google Scholar 

  31. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study of taxol in patients with advanced ovarian cancer. Proc Am Assoc Cancer Res 31:187, 1990.

    Google Scholar 

  32. Thigeen T, Blessing J, Ball H, et al. Phase II trial of taxol as second-line therapy for ovarian cancer: a Gynecologic Oncology Group Study. Proc Am Soc Clin Oncol 9:156, 1990.

    Google Scholar 

  33. Swindell CS, Patel BP, deSolms SJ, et al. A route for the construction of the taxane BC substructure. J Org Chem 52:2346–2355, 1987.

    Article  CAS  Google Scholar 

  34. Parness J, Kingston GI, Powell RG, et al. Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxones. Biochem Biophys Res Commun 105:1082–1089, 1982.

    Article  PubMed  CAS  Google Scholar 

  35. Manfredi JJ and Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmac Ther 25:83–125, 1984.

    Article  CAS  Google Scholar 

  36. Masurovsky EB, Peterson ER, Crain SM, et al. Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures. Brain Res 217:392–398, 1981.

    Article  PubMed  CAS  Google Scholar 

  37. Masurovsky EB, Peterson ER, Crain SM, et al. Taxol-induced microtubule formations in

    Google Scholar 

  38. Masurovsky EB, Peterson ER, Crain SM, et al. Morphologic alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol. Neuroscience 10:491–509, 1983.

    Article  PubMed  CAS  Google Scholar 

  39. Mole-Bajar J and Bajar AS. Action of taxol on mitosis: Modification of microtubule arrangements and function of the mitotic spindle in hoemanthus endosperm. J Cell Biol 96:527–540, 1983.

    Article  Google Scholar 

  40. Letourneau PC and Ressler AH. Inhibition of neurite initiation and growth by taxol. J Cell Biol 98:1355–1362, 1984.

    Article  PubMed  CAS  Google Scholar 

  41. Letourneau PC, Shattuck T, Ressler AH. Branching of sensory and sympathetic neurites in vitro is inhibited by treatment with taxol. J neuroscience 6:1912–1917, 1986.

    CAS  Google Scholar 

  42. Roytta M, Horwitz SB, Raine CS. Taxol induced neuropathy: Short term effects of local injection. J Neurocytology 13:685–701, 1984.

    Article  CAS  Google Scholar 

  43. Roytta M and Raine CS. Taxol induced neuropathy: Further ultrastructural studies of nerve fiber changes in situ. J Neurocytology 14:157–175, 1985.

    Article  CAS  Google Scholar 

  44. Roytta M and Raine CS. Taxol induced neuropathy: Chronic effects of local injection. J Neurocytology 15:483–496, 1986.

    Article  CAS  Google Scholar 

  45. Crain S and Peterson E. Enhanced dependence of fetal mouse neurons on trophic factors after taxol exposure in organotypic cultures. In Cellular and Mollecular Biology of Neuronal Development, IB Block (ed). Plenum Publishing, New York, 1984.

    Google Scholar 

  46. Lipton RB, Apfel S, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. 39:368–373, 1989.

    CAS  Google Scholar 

  47. Peterson E and Crain S. Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice. Science 217:377–379, 1982.

    Article  PubMed  CAS  Google Scholar 

  48. Roy SN and Horwitz SB. A phosphoglycoprotein associated with taxol-resistance in J7874.2 cells. Cancer Res 45:3856–3863, 1985.

    PubMed  CAS  Google Scholar 

  49. Horwitz SB, Schiff PB, Parness J, et al. Taxol: A Probe for studying the structure and function of microtubules. In: The Cytoskeleton, Clarkson TW (ed). Plenum Publishing, New York, 1986.

    Google Scholar 

  50. Horwitz SB, Goei S, Greenberger L, et al. Resistance in the mouse macrophage-like cell line J774–2. In: Mechanisms Of Drug Resistance in Neoplastic Cells, Bristol-Myers Cancer Symposium Vol. 9, PV Woolley III, KD Tew (eds). Academic Press, San Diego, 1988, pp. 223–242.

    Google Scholar 

  51. Ling V and Kartner N. Multidrug resistance in cancer. Scient Am 260:44–51, 1989.

    Article  Google Scholar 

  52. Gerlach JH, Kartner N, Bell DR, et al. Multidrug resistance. Can Surv 5:25–46, 1986.

    CAS  Google Scholar 

  53. Pastan I and Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393, 1987.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Avi I. Einzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter H. Wiernik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward L. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Southern California Cancer Center, USA

    F. M. Muggia

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Kluwer Academic Publishers, Boston.

About this chapter

Cite this chapter

Einzig, A.I., Wiernik, P.H., Schwartz, E.L. (1992). Taxol: A new agent active in melanoma and ovarian cancer. In: Muggia, F.M. (eds) New Drugs, Concepts and Results in Cancer Chemotherapy. Cancer Treatment and Research, vol 58. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3876-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3876-9_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-1253-6

  • Online ISBN: 978-1-4615-3876-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation